Cargando…

Impact of Lung Function and Exacerbations on Health-Related Quality of Life in COPD Patients Within One Year: Real-World Analysis Based on Claims Data

PURPOSE: Real-world evidence on the impact of forced expiratory volume in one second (FEV(1)) and exacerbations on health-related quality of life (HRQoL) in patients with chronic obstructive pulmonary disease (COPD) is sparse especially with regard to GOLD ABCD groups. This study investigates how ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Stöber, Alisa, Lutter, Johanna I, Schwarzkopf, Larissa, Kirsch, Florian, Schramm, Anja, Vogelmeier, Claus F, Leidl, Reiner
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473986/
https://www.ncbi.nlm.nih.gov/pubmed/34588773
http://dx.doi.org/10.2147/COPD.S313711
_version_ 1784575120367419392
author Stöber, Alisa
Lutter, Johanna I
Schwarzkopf, Larissa
Kirsch, Florian
Schramm, Anja
Vogelmeier, Claus F
Leidl, Reiner
author_facet Stöber, Alisa
Lutter, Johanna I
Schwarzkopf, Larissa
Kirsch, Florian
Schramm, Anja
Vogelmeier, Claus F
Leidl, Reiner
author_sort Stöber, Alisa
collection PubMed
description PURPOSE: Real-world evidence on the impact of forced expiratory volume in one second (FEV(1)) and exacerbations on health-related quality of life (HRQoL) in patients with chronic obstructive pulmonary disease (COPD) is sparse especially with regard to GOLD ABCD groups. This study investigates how changes in FEV(1) and exacerbations affect generic and disease-specific HRQoL in COPD patients over one year. METHODS: Using German claims data and survey data, we classified 3016 COPD patients and analyzed their health status by GOLD groups AB and CD. HRQoL was measured with the disease-specific COPD assessment test (CAT) and the visual analog scale (VAS) from the generic Euro-Qol 5D-5L. We applied change score models to assess associations between changes in FEV(1) (≥100 mL decrease/no change/≥100 mL increase) or the development of severe exacerbations with change in HRQoL. RESULTS: FEV(1) decrease was associated with a significant but not minimal important difference (MID) deterioration in disease-specific HRQoL (mean change [95% CI]: CAT +0.74 [0.15 to 1.33]), while no significant change was observed in the generic VAS. Experiencing at least one severe exacerbation also had a significant impact on CAT deterioration (+1.58 [0.52 to 2.64]), but again not on VAS. Here, GOLD groups AB showed not only a statistically but also a clinically relevant MID deterioration in CAT (+2.1 [0.88 to 3.32]). These particular patient groups were further characterized by a higher probability of being male, having a higher mMRC and Charlson index, and a lower probability of having higher FEV(1) or BMI values. CONCLUSION: FEV(1) decline and the occurrence of ≥1 severe exacerbation are significantly associated with overall deterioration in disease-specific HRQoL. Preventing severe exacerbations particularly in patients without previous severe exacerbations (ABCD groups A and B) may help to stabilize the key patient-reported outcome HRQoL.
format Online
Article
Text
id pubmed-8473986
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-84739862021-09-28 Impact of Lung Function and Exacerbations on Health-Related Quality of Life in COPD Patients Within One Year: Real-World Analysis Based on Claims Data Stöber, Alisa Lutter, Johanna I Schwarzkopf, Larissa Kirsch, Florian Schramm, Anja Vogelmeier, Claus F Leidl, Reiner Int J Chron Obstruct Pulmon Dis Original Research PURPOSE: Real-world evidence on the impact of forced expiratory volume in one second (FEV(1)) and exacerbations on health-related quality of life (HRQoL) in patients with chronic obstructive pulmonary disease (COPD) is sparse especially with regard to GOLD ABCD groups. This study investigates how changes in FEV(1) and exacerbations affect generic and disease-specific HRQoL in COPD patients over one year. METHODS: Using German claims data and survey data, we classified 3016 COPD patients and analyzed their health status by GOLD groups AB and CD. HRQoL was measured with the disease-specific COPD assessment test (CAT) and the visual analog scale (VAS) from the generic Euro-Qol 5D-5L. We applied change score models to assess associations between changes in FEV(1) (≥100 mL decrease/no change/≥100 mL increase) or the development of severe exacerbations with change in HRQoL. RESULTS: FEV(1) decrease was associated with a significant but not minimal important difference (MID) deterioration in disease-specific HRQoL (mean change [95% CI]: CAT +0.74 [0.15 to 1.33]), while no significant change was observed in the generic VAS. Experiencing at least one severe exacerbation also had a significant impact on CAT deterioration (+1.58 [0.52 to 2.64]), but again not on VAS. Here, GOLD groups AB showed not only a statistically but also a clinically relevant MID deterioration in CAT (+2.1 [0.88 to 3.32]). These particular patient groups were further characterized by a higher probability of being male, having a higher mMRC and Charlson index, and a lower probability of having higher FEV(1) or BMI values. CONCLUSION: FEV(1) decline and the occurrence of ≥1 severe exacerbation are significantly associated with overall deterioration in disease-specific HRQoL. Preventing severe exacerbations particularly in patients without previous severe exacerbations (ABCD groups A and B) may help to stabilize the key patient-reported outcome HRQoL. Dove 2021-09-21 /pmc/articles/PMC8473986/ /pubmed/34588773 http://dx.doi.org/10.2147/COPD.S313711 Text en © 2021 Stöber et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Stöber, Alisa
Lutter, Johanna I
Schwarzkopf, Larissa
Kirsch, Florian
Schramm, Anja
Vogelmeier, Claus F
Leidl, Reiner
Impact of Lung Function and Exacerbations on Health-Related Quality of Life in COPD Patients Within One Year: Real-World Analysis Based on Claims Data
title Impact of Lung Function and Exacerbations on Health-Related Quality of Life in COPD Patients Within One Year: Real-World Analysis Based on Claims Data
title_full Impact of Lung Function and Exacerbations on Health-Related Quality of Life in COPD Patients Within One Year: Real-World Analysis Based on Claims Data
title_fullStr Impact of Lung Function and Exacerbations on Health-Related Quality of Life in COPD Patients Within One Year: Real-World Analysis Based on Claims Data
title_full_unstemmed Impact of Lung Function and Exacerbations on Health-Related Quality of Life in COPD Patients Within One Year: Real-World Analysis Based on Claims Data
title_short Impact of Lung Function and Exacerbations on Health-Related Quality of Life in COPD Patients Within One Year: Real-World Analysis Based on Claims Data
title_sort impact of lung function and exacerbations on health-related quality of life in copd patients within one year: real-world analysis based on claims data
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473986/
https://www.ncbi.nlm.nih.gov/pubmed/34588773
http://dx.doi.org/10.2147/COPD.S313711
work_keys_str_mv AT stoberalisa impactoflungfunctionandexacerbationsonhealthrelatedqualityoflifeincopdpatientswithinoneyearrealworldanalysisbasedonclaimsdata
AT lutterjohannai impactoflungfunctionandexacerbationsonhealthrelatedqualityoflifeincopdpatientswithinoneyearrealworldanalysisbasedonclaimsdata
AT schwarzkopflarissa impactoflungfunctionandexacerbationsonhealthrelatedqualityoflifeincopdpatientswithinoneyearrealworldanalysisbasedonclaimsdata
AT kirschflorian impactoflungfunctionandexacerbationsonhealthrelatedqualityoflifeincopdpatientswithinoneyearrealworldanalysisbasedonclaimsdata
AT schrammanja impactoflungfunctionandexacerbationsonhealthrelatedqualityoflifeincopdpatientswithinoneyearrealworldanalysisbasedonclaimsdata
AT vogelmeierclausf impactoflungfunctionandexacerbationsonhealthrelatedqualityoflifeincopdpatientswithinoneyearrealworldanalysisbasedonclaimsdata
AT leidlreiner impactoflungfunctionandexacerbationsonhealthrelatedqualityoflifeincopdpatientswithinoneyearrealworldanalysisbasedonclaimsdata